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Extracellular high-mobility group box (HMGB)1 mediates inflammation
during sterile and infectious injury and contributes importantly to
disease pathogenesis. The first critical step in the release of HMGB1
from activated immune cells is mobilization from the nucleus to the
cytoplasm, a process dependent upon hyperacetylation within two
HMGB1 nuclear localization sequence (NLS) sites. The inflammasomes
mediate the release of cytoplasmic HMGB1 in activated immune cells,
but the mechanism of HMGB1 translocation from nucleus to cytoplasm
was previously unknown. Here, we show that pharmacological inhibition of JAK/STAT1 inhibits LPS-induced HMGB1 nuclear translocation. Conversely, activation of JAK/STAT1 by type 1 interferon (IFN)
stimulation induces HMGB1 translocation from nucleus to cytoplasm.
Mass spectrometric analysis unequivocally revealed that pharmacological inhibition of the JAK/STAT1 pathway or genetic deletion of
STAT1 abrogated LPS- or type 1 IFN-induced HMGB1 acetylation
within the NLS sites. Together, these results identify a critical role of
the JAK/STAT1 pathway in mediating HMGB1 cytoplasmic accumulation for subsequent release, suggesting that the JAK/STAT1
pathway is a potential drug target for inhibiting HMGB1 release.
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igh-mobility group box 1 (HMGB1), a ubiquitous DNAbinding protein, is a promiscuous sensor driving nucleic acidmediated immune responses and a pathogenic inflammatory
mediator in sepsis, arthritis, colitis, and other disease syndromes
(1–5). Immune cells actively release HMGB1 after activation by
exposure to pathogen-associated molecular patterns or damageassociated molecular patterns, including lipopolysaccharide (LPS)
and inflammasome agonists (1, 6, 7). High levels of extracellular
HMGB1 accumulate in patients with infectious and sterile inflammatory diseases. Extracellular disulfide HMGB1 stimulates
macrophages to release TNF and other inflammatory mediators
by binding and signaling through Toll-like receptor (TLR)4.
Reduced HMGB1 facilitates immune cell migration by interacting with the receptor for advanced glycation end products (RAGE) and CXCL12 (8–12), a process regulated by
posttranslational redox-dependent mechanisms. Administration of neutralizing anti-HMGB1 mAbs or other HMGB1 antagonists significantly reduces the severity of inflammatory disease,
promotes bacterial clearance during Pseudomonas aeruginosa
or Salmonella typhimurium infection and attenuates memory
impairment in sepsis survivors (1, 13–15). Together, these and
other findings indicate the importance of a mechanistic understanding of HMGB1 release from activated immune cells and
the regulatory signaling pathways controlling these processes.
Most cytokines harbor a leader peptide that facilitates secretion through the endoplasmic reticulum–Golgi exocytotic route.
HMGB1, which lacks a leader peptide, is released via unconventional protein secretion pathways (1, 6, 7). In quiescent
cells, most HMGB1 is localized in the nucleus. Upon activation
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of immune cells, efficient HMGB1 release requires acetylation
of HMGB1 within the two nuclear localization sequence (NLS)
sites and subsequent HMGB1 accumulation in the cytoplasm (1,
6, 16–20). HMGB1 release is mediated by inflammasome activation during pyroptosis, a form of proinflammatory programmed
cell death (6, 7, 22–24). Protein kinase (PK)R is a critical regulator
of inflammasome-dependent HMGB1 release (6, 25). Pharmacological inhibition of PKR abrogates LPS-induced HMGB1
release by macrophages but does not prevent nuclear translocation of HMGB1 to cytoplasm. This suggests that some
other, as yet unknown, inflammasome-independent pathway regulates HMGB1 translocation from nucleus to cytoplasm.
We and others have previously established an important role
of type 1 and type 2 interferons (IFNs) and downstream JAK/
STAT1 signaling activation in mediating HMGB1 release (26–
28). Pharmacological inhibition of JAK/STAT, genetic deletion
of STAT1, or inhibition of extracellular IFN-β with neutralizing
antibodies significantly abrogates LPS-induced HMGB1 release
from macrophages (26–28). Importantly, pharmacological inhibition of the JAK/STAT1 pathway, genetic deletion of STAT1,
or inhibition of IFN-β expression by genetic deletion of IRF3
significantly promotes survival in both lethal endotoxemia and
experimental sepsis (28–30). Accordingly, we reasoned here that
JAK/STAT1 may represent a critical signaling mechanism controlling HMGB1 translocation from nucleus to cytoplasm.
Significance
High-mobility group box (HMGB)1 is a nuclear protein that we
have identified as a proinflammatory mediator during infection
or sterile tissue injury, which importantly orchestrates the innate immune responses. The mechanisms of HMGB1 release
require translocation of HMGB1 from nucleus to cytoplasm and
release into the extracellular space. We recently reported that
the inflammasome and PKR mediates HMGB1 release from the
cytoplasm, but the mechanism of HMGB1 translocation from
nucleus to cytoplasm was previously unknown. Here, we describe our discovery that JAK/STAT1 is required for LPS- or interferon-induced HMGB1 nuclear translocation. These findings
have significant implications for the field, and for designing
therapeutics for potential use in inflammatory diseases.
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Pharmacological Inhibition of the JAK/STAT Pathway Blocks LPSInduced HMGB1 Nuclear Translocation and Release. To investigate

the role of the JAK/STAT pathway in LPS-induced HMGB1
nuclear translocation, mouse macrophage-like RAW 267.4 cells
were stimulated by addition of LPS in the presence of the JAK/
STAT inhibitor pyridone 6. HMGB1 cytoplasmic accumulation
was assessed by immunostaining and HMGB1 levels in the cell
culture medium assessed by Western blot. As expected, LPS
induced robust HMGB1 cytoplasmic accumulation. Inhibition of
JAK/STAT significantly blocked LPS-induced HMGB1 translocation to cytoplasm (Fig. 1 A and B and SI Appendix, Fig. S1)
and HMGB1 release (Fig. 1C), which is correlated with LDH
levels in the cell culture medium (Fig. 1D). Inhibition of JAK/
STAT failed to decrease LPS-induced secretion of TNF, IL-10,
RANTES, IL-12p70, and MCP-1 (Fig. 1E and SI Appendix, Figs.
S2 and S3). Next, we sought to determine whether JAK/STAT
signaling specifically regulates LPS-induced HMGB1 cytoplasmic accumulation. RAW 267.4 cells were stimulated by rapamycin, which induces HMGB1 cytoplasmic accumulation but
does not activate JAK/STAT (31). Notably, pyridone 6 failed to
inhibit rapamycin-induced HMGB1 cytoplasmic accumulation
(SI Appendix, Fig. S4). Cytoplasmic accumulation of HMGB1
promotes autophagy (31, 32). Pyridone 6 significantly inhibited
LPS-induced, but not rapamycin-induced, autophagy in RAW
267.4 cells (SI Appendix, Figs. S5 and S6). Together, these results
indicate that JAK/STAT specifically mediates LPS-induced
HMGB1 cytoplasmic accumulation.
Activation of the JAK/STAT Pathway by Type 1 IFN Induces HMGB1
Cytoplasmic Accumulation and Release. IFN-β stimulates HMGB1

JAK/STAT1 Is Required for LPS- or IFN-β–Induced HMGB1 Acetylation
Within NLS Sites. HMGB1 acetylation at two NLS sites is required

for the nuclear translocation and cytoplasmic accumulation of
HMGB1 (17). LPS stimulation rapidly induces hyperacetylation
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release, which is dependent, in part, on JAK/STAT (26, 27). To

establish the role of the JAK/STAT signaling for HMGB1 cytoplasmic accumulation, RAW 267.4 cells were stimulated with
IFN-β in the presence or absence of the JAK/STAT pathway
inhibitor pyridone 6. As revealed by fluorescent immunochemical staining, IFN-β stimulation induced cytoplasmic accumulation of HMGB1 (SI Appendix, Figs. S7 and S8); IFN-β and IFN-α
stimulation induced HMGB1 release in a time- and dose-dependent
manner (Fig. 2 A and B). Pyridone 6 dose-dependently inhibited
IFN-β–induced HMGB1 cytoplasmic accumulation, HMGB1
secretion, and LDH release (Fig. 2C and SI Appendix, Figs. S7–
S9). This response is cell type-specific, because IFN-β failed to
increase HMGB1 release in mouse embryonic fibroblasts (SI
Appendix, Fig. S10). Together, this indicates that JAK/STAT is
required for IFN-β–induced HMGB1 cytoplasmic accumulation
and release in RAW 267.4 cells. We and others recently revealed
that secretion of HMGB1 from cytoplasm into the extracellular
space requires activation of the inflammasome and PKR (6).
Accordingly, we next hypothesized that JAK/STAT regulation of
HMGB1 nuclear translocation preceded inflammasome- and
PKR-dependent secretion. To test this possibility, we assessed
HMGB1 nucleus to cytoplasm translocation in the presence of
PKR inhibitors; 2-aminopurine (2-AP) failed to block IFNβ–induced HMGB1 nucleus to cytoplasm translocation (SI Appendix, Fig. S8), even though 2-AP dose-dependently inhibited
IFN-β–induced HMGB1 release (Fig. 2D). Thus, JAK/STAT
signals mediate mobilization of HMGB1 from the nucleus to the
cytoplasm, and PKR-dependent inflammasome activation
mediates secretion.
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Results

Fig. 1. Pharmacological inhibition of the JAK/STAT pathway blocks LPS-induced HMGB1 nuclear translocation and release. (A–D) Mouse macrophage-like
RAW 267.4 cells were stimulated with LPS in the absence or the present of pyridone 6 for 16h. The localization of cellular HMGB1 was measured by fluorescent immunostaining analysis. (Scale bars, 20 μm.) Shown in A are representative images of HMGB1 immunostaining, and shown in B are means ± SEM of
two independent experiments. The levels of HMGB1 in the culture medium were measured by Western blot analysis (C). Cytotoxicity was determined by LDH
assay (D). (E) Mouse macrophages were stimulated with LPS in the absence or the present of pyridone 6 for 6 h. The levels of TNF in the culture medium were
assessed by ELISA. Data shown are means ± SEM of two independent experiments. #P < 0.05.
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Fig. 2. Activation of the JAK/STAT pathway by type 1 IFN induces HMGB1
release. (A and B) RAW 267.4 cells were stimulated with IFN-α and IFN-β
at various concentrations (A) for the indicated time (B). The levels of HMGB1
in the culture medium were measured by Western blot analysis. (C and D)
RAW 267.4 cells were stimulated with IFN-β (100 U/mL) in the absence or
the present of pyridone 6 (C ) or 2-AP (D) at various concentrations for
16 h. The levels of HMGB1 in the culture medium were measured by
Western blot analysis.

of HMGB1 (17). To confirm this phenomenon, monocytic THP-1
cells were stimulated with LPS for 3h. High-resolution liquid
chromatography–tandem mass spectrometric analysis (LC-MS/
MS) revealed that HMGB1 was constitutively acetylated at the
lysine residues 111, 113, 171, 172, and 176. Following LPS
stimulation, significant acetylation was observed at the lysine
residues 2, 6, 7, 11, 27, 28, 29, 42, 43, 179, 181, 183, and 184.
Notably, lysine residues 28, 29, 42, and 43 are located within the
first NLS of HMGB1, whereas lysine residues 179, 181, 183, and
184 are located within the second NLS of HMGB1 (SI Appendix,
Figs. S11–S13). Thus, LPS stimulation induces lysine acetylation
within both HMGB1 NLS sites.
To elucidate the mechanism by which JAK/STAT regulates
HMGB1 nucleus to cytoplasm translocation, we next determined
whether JAK/STAT is required for LPS- or IFN-β–induced
HMGB1 acetylation within NLS sites. We observed the appearance of peptides with molecular masses of 1,749.8 and
1,342.3 Da, corresponding to hyperacetylated NLS1 and NLS2,
respectively (Fig. 3A). These peptides were absent from unstimulated macrophages, which contained only peptides of molecular
masses 1,623.4 and 1,132.4 Da corresponding to hypoacetylated
NLS1 and NLS2, respectively (Fig. 3A). The increased mass
shifts of 126 Da for NLS1 and 210 Da for NLS2 in stimulated
macrophage samples represent the presence of either 3× acetyl
or 5× acetyl modifications on NLS1 and NLS2. Addition of the
JAK/STAT inhibitor, pyridone 6, significantly inhibited LPS- and
IFN-β–induced HMGB1 acetylation at the NLSs (Fig. 3A).
Genetic deletion of STAT1 abrogates LPS- and IFN-induced
HMGB1 acetylation within the NLS sites (Fig. 3B). Together,
these observations establish that JAK/STAT1 is required for
LPS- and IFN-β–induced HMGB1 acetylation within both
NLS sites.
JAK/STAT1 Is Dispensable for LPS- or IFN-β–Induced HMGB1 Disulfide
Bond Formation Between Cys23 and Cys45. HMGB1 contains three

redox-sensitive cysteine residues (Cys): Cys23, Cys45, and Cys106.
3070 | www.pnas.org/cgi/doi/10.1073/pnas.1316925111

The redox status of these cysteines determines HMGB1 biological activity (8, 11). In this context, fully reduced HMGB1
forms a complex with CXCL12 and promotes migration of immune cells via CXCR4; partially oxidized HMGB1 with a thiol
form of Cys106 and a disulfide bond between Cys23 and Cys45
triggers inflammatory responses via TLR4, whereas cysteine alloxidized HMGB1 has neither cytokine nor chemotactic activity
(8, 11). In resting macrophages, the intracellular HMGB1 pool
was dominated by the fully reduced form of HMGB1. However,
stimulation of macrophages with LPS markedly induces the
formation of HMGB1 bearing disulfide bonds between Cys23
and Cys45 (6). Thus, it remained theoretically possible that JAK/
STAT1 signaling is required for LPS-induced disulfide bond
formation between Cys23 and Cys45. To test this hypothesis, we
stimulated wild-type (WT) or STAT1 knockout (KO) mouse
macrophages with LPS or IFN-β in the absence or the presence
of JAK/STAT inhibitors. Intracellular HMGB1 was enzymatically digested into small peptides and subjected to LC-MS/MS
analysis. Both LPS and IFN-β stimulation induced HMGB1
disulfide bond formation between Cys23 and Cys45, as indicated
by the presence of peptide with masses of Cys23 (1,564.7 Da)
and Cys45 (618.1 Da) after LPS or IFN-β stimulation (Fig. 4).
Cys106 of HMGB1 was present in a thiol form in both stimulated
and nonstimulated cells, as indicated by the presence of peptide
with masses of Cys106 (2,002.1 Da) (Fig. 4). Analysis of b and y
ions generated from these peptides confirmed the amino acid
sequence of each peptide, the disulfide bond between Cys23 and
Cys45, and the thiol form of Cys106. Notably, LPS or IFNβ–induced HMGB1 disulfide bond formation between Cys23 and
Cys45 was not inhibited by pyridone 6, as revealed by LC-MS/MS
analysis that the presence of peptide with masses of Cys23
(1,564.7 Da) and Cys45 (618.1 Da) was not affected by the addition of pyridone 6 to macrophages (SI Appendix, Fig. S14).
Furthermore, the levels of HMGB1 isoform expressing a disulfide bond were comparable between the STAT1-deficient macrophages and their WT controls (Fig. 4), in contrast to levels of
the HMGB1 isoform expressing hyperacetylation within NLS
sites (Fig. 3B). Taken together, JAK/STAT1 signals are required
for LPS- or IFN-β–induced HMGB1 hyperacetylation within
NLS sites and nucleus to cytoplasm translocation of HMGB1
but not disulfide bond formation between Cys23 and Cys45.
Discussion
Protein shuttling between nucleus and cytoplasm depends upon
NLS and nuclear export sequences (NES) (16). Posttranslational
modifications of these NLS or NES critically regulate the subcellular localization of intracellular proteins (16). HMGB1
contains two NLS sites, directing its nuclear localization. Inflammation or cell stress induces acetylation of HMGB1 at the
NLS sites, preventing nuclear reentry and leading to HMGB1
accumulation in the cytoplasm (17–20). In this study, we identified a key role of JAK/STAT1 in HMGB1 hyperacetylation and
cytoplasmic accumulation. Together with recent findings that
caspase-1 or caspase-11 mediates HMGB1 release via pyroptosis
(6, 7, 21–24), we here propose two critical steps for HMGB1
release from LPS-activated immune cells. In the first step, LPS
activates the TLR4/TRIF/IFN-β signaling cascade and the downstream JAK/STAT1 pathway, which is required for LPS-induced
HMGB1 hyperacetylation within NLS sites and HMGB1 cytoplasmic accumulation. JAK/STAT1 mediates LPS-induced IRF1
expression in macrophages (33). Recent findings reveal that IRF1
promotes HMGB1 acetylation via physical association with histone acetylases and is required for LPS-induced HMGB1 cytoplasmic accumulation and release (34, 35). LPS also activates
calcium/calmodulin-dependent protein kinase (CaMK) IV, which
culminates in HMGB1 serine phosphorylation, a posttranslational
modification that also promotes HMGB1 cytoplasmic accumulation
(19). In the second step, endogenous danger signals or pathogens
Lu et al.
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induce canonical or noncanonical inflammasome activation, which,
in turn, activates caspase-1 or caspase-11, respectively. This mediates pyroptosis and cytoplasmic HMGB1 release into to the extracellular space (SI Appendix, Fig. S15). Understanding these
mechanisms by which immune cells regulate HMGB1 release
may enable targeting therapeutics to attenuate HMGB1-related
inflammation by selective inhibition of the JAK/STAT1 pathway
or caspase-mediated pathway.
Caspase-11 enhances the production of IL-1β and IL-18 by
interacting with caspase-1 (36). However, caspase-11 can also
induce pyroptosis and HMGB1 release independently of caspase-1
and other inflammasome components (21, 23). The important
interplay between caspase-11 and HMGB1 during systemic
inflammation is revealed by the fact that genetic deletion of
caspase-11 or administration of neutralizing anti-HMGB1
antibodies significantly promotes survival during lethal endotoxemia, enhances bacterial clearance during P. aeruginosa or
S. typhimurium infection, and prevents cognitive decline after
experimental polymicrobial sepsis (1, 12–15, 22). In contrast,
selective gene deletions for IL-1β and IL-18 fails to promote
survival during lethal endotoxemia (22), and loss of NLRP3, a
canonical inflammasome component, enhances mortality during
Lu et al.

bacterial or fungal infections (24, 37). Inhibition of global inflammatory responses by genetic deletion of IKKβ and interleukin 1 receptor type 1 generates severe immune deficiency
against bacterial infections (38). Together, these findings emphasize the importance of selectively targeting damage-mediated
inflammation while preserving the physiological protective immune responses.
Notably, pharmacological inhibition of the JAK/STAT1
pathway or genetic deletion of STAT1 did not decrease the
production of other proinflammatory cytokines and chemokines.
Thus, it may be possible to target the JAK/STAT1 pathway to
selectively inhibit HMGB1 release without significantly compromising innate immune responses. It is also important to
note that the modulation of the JAK/STAT1 pathway by either
pharmacological or genetic manipulation altered the HMGB1
redox-dependent isoform pattern when cells were exposed to
IFN-β but not to LPS stimulation. These data indicate that the
mechanisms that regulate HMGB1 release and nuclear translocation are intimately linked to the biological functions of
the secreted HMGB1 (11). Recent studies reveal that the
TLR4/TRIF/IFN-β signaling cascade and the downstream JAK/
STAT1 pathway are important for caspase-11 expression and
PNAS | February 25, 2014 | vol. 111 | no. 8 | 3071
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Fig. 3. JAK/STAT1 is required for LPS- or IFN-β–induced HMGB1 acetylation within NLS sites. (A) Mouse peritoneal macrophages were stimulated with indicated
stimuli in the absence or the presence of pyridone 6 for 6 h. (B) Mouse peritoneal macrophages isolated from WT or STAT1 KO mice were stimulated with indicated
stimuli for 6 h. The acetylation of intracellular HMGB1 protein within the NLS sites was assessed using LC-MS/MS. Shown are representative MS traces.

Fig. 4. JAK/STAT1 signaling is dispensable for LPS- or IFN-induced HMGB1 oxidation. Mouse peritoneal macrophages isolated from WT or STAT1 KO mice
were stimulated with indicated stimuli for 6 h. The redox status of intracellular HMGB1 protein was assessed by LC-MS/MS. Shown in the graphs are representative MS traces.

activation (23, 36), which further emphasizes the critical role of
the JAK/STAT1 pathway in inflammatory responses. In line
with this, pharmacological inhibition of the JAK/STAT1 pathway, genetic deletion of STAT1, or inhibition of IFN-β expression by knock out of IRF3, significantly inhibits HMGB1
release and enhances survival in both lethal endotoxemia and
experimental sepsis (28–30). Together, these findings indicate
that targeting the JAK/STAT1 pathway may be beneficial in
treating inflammation.
Materials and Methods
Reagents. LPS (Escherichia coli; 0111:B4) and PKR inhibitor 2-AP were purchased from Sigma-Aldrich. JAK inhibitor pyridone 6 was obtained from
Calbiochem and Cell Signaling Technology.
Recombinant mouse IFN-α and IFN-β were purchased from R&D Systems.
Mouse anti-HMGB1 mAb IgG2b 2G7 (noncommercial antibody) was originally from Critical Therapeutic (available upon request). Anti-LC3B antibodies were obtained from Cell Signaling Technology (catalog no. 2775).
Cell Isolation and Culture. Murine macrophage-like RAW 264.7 cells (American
Type Culture Collection) were cultured in RPMI medium 1640 supplemented
with 10% (vol/vol) FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin.
Cells were used at 90% confluence and treatment was carried out in reducedserum Opti-MEM I medium. Peritoneal mouse macrophages were isolated as
described previously. Cells were cultured in RPMI medium 1640 supplemented
with 10% (vol/vol) FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin.
Macrophages were gently washed with, and cultured in, reduced-serum
OPTI-MEM I medium before stimulation with LPS or type 1 IFNs. At 16 h after
stimulation, levels of various cytokines in the culture medium were determined by ELISA.
ELISA. TNF and IL-10 levels in the culture medium were determined using
quantitative ELISA kits (MTA00; R&D Systems), with reference to standard
curves of purified recombinant TNF or IL-10 at various dilutions.
HMGB1 Western Blotting Analysis. The relative levels of HMGB1 in the culture
medium were determined by Western blotting analysis as described previously
(6, 26, 39). The relative band intensity was quantified by using the NIH image
1.59 software to determine HMGB1 levels, with reference to standard curves
generated with purified HMGB1 as described previously (6, 24, 40).
Immunohistochemical Staining. Immunohistochemical staining was performed
as described previously (26, 39). Briefly, mouse macrophage-like RAW 264.7
cells were plated in 24-well chamber slides in DMEM supplemented with
10% (vol/vol) FBS. After 16 h of stimulation, cells were washed twice with
ice-cold PBS. Cells were fixed and permeabilized using 0.2% of Triton X-100,
blocked with 10% (vol/vol) normal goat serum, and incubated with primary
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antibodies followed by Alexa Fluor 488 goat anti-mouse IgG (Invitrogen)
before mounting. Images were captured by a confocal laser-scanning microscope or a Zeiss Axiovert microscope. HMGB1 cytoplasmic accumulation was
assessed by counting the percentage of cells with visible cytoplasmic HMGB1
staining from at least four randomly selected microscopic fields. (The average cell
number in each microscopic field is around 70.)
Autophagy Assays. Autophagy was evaluated in cells by fluorescence Zeiss
Axiovert microscope or Western blot. In fluorescence microscopy experiments, macrophage-like RAW 264.7 cells stably transfected with GFP-LC3
(provided by N. Tony Eissa, Department of Medicine, Baylor College of Medicine,
Houston) were stimulated with LPS or rapamycin in the absence or presence
of pyridone 6 for 16 h, and cells were examined for the presence of GFP-LC3
punctate structures under a Zeiss Axiovert microscope as described previously (39). Quantitation of autophagy was performed based on the percentage of cells that contain GFP-LC3–positive autophagic punctate dots.
In the Western blot experiments, the levels of 18-kDa cytosolic LC3-I and
16-kDa lipidated autophagosome-bound LC3-II were determined by Western
blot as described previously.
HMGB1 Preparation for LC-MS/MS Analysis. All chemicals and solvents were of
the highest available grade (Sigma). Culture supernatants were precleared
with 50 μL of protein G–Sepharose beads for 1 h at 4 °C. Supernatant HMGB1
was immunoprecipitated with 5 mg of a polyclonal rabbit anti-HMGB1 antibody (Abcam; ab18256) for 16 h at 4 °C. Free thiol groups within HMGB1 were
alkylated for 90 min with 10 mM iodoacetamide at 4 °C. Cysteine residues in
disulfide bonds were then reduced with 30 mM DTT at 4 °C for 1 h, followed
by alkylation of newly exposed thiol groups with 90 mM NEM at 4 °C for
10 min. Samples were subjected to trypsin (Promega) or GluC (New England
Biolabs) digestion according to the manufacturer’s instructions for redox or
acetyl modification analysis, respectively, and desalted using ZipTip C18 pipette tips (Millipore). Characterization of cysteine bonds and absolute quantification of acetylated HMGB1 was determined as described (6), whereas
redox analysis was performed as described previously (11, 40, 41) using an AB
Sciex TripleTOF 5600 (Sciex). Analysis of b and y ions generated during MS/MS
from these peptides confirmed the amino acid sequence of each peptide and
the presence of posttranslational modifications.
Statistical Analysis. Data are expressed as means ± SD of at least three independent experiments (n = 3–5). One-way analysis of variance was used for
comparison among all different groups. A P value of <0.05 was considered
statistically significant.
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